Loading company
IOVANCE BIOTHERAPEUTICS, INC. (IOVA) financials: quick answers
Annual figures as filed with the SEC. Each number links to the filing it came from and to its proof.
| Metric | FY2025 | FY2024 | Change | Source |
|---|---|---|---|---|
| Revenue | $263.5 million | $164.1 million | +60.6% | 10-K 2026-02-24 · proof |
| Gross profit | $90.3 million | $70.8 million | +27.5% | 10-K 2026-02-24 · proof |
| Operating income | -$403.4 million | -$395.3 million | 10-K 2026-02-24 · proof | |
| Net income | -$391 million | -$372.2 million | 10-K 2026-02-24 · proof | |
| Cash from operating activities | -$302.4 million | -$353 million | 10-K 2026-02-24 · proof | |
| Free cash flow | -$336.2 million | -$364 million | 10-K 2026-02-24 · proof | |
| Total assets | $913.2 million | $910.4 million | +0.3% | 10-K 2026-02-24 · proof |
| Total liabilities | $214.6 million | $200 million | +7.3% | 10-K 2026-02-24 · proof |
| Cash and cash equivalents | $163.1 million | $115.7 million | +41% | 10-K 2026-02-24 · proof |
- What was IOVANCE BIOTHERAPEUTICS, INC. (IOVA)'s revenue in fiscal 2025?
- IOVANCE BIOTHERAPEUTICS, INC. (IOVA) reported revenue of $263.5 million for fiscal 2025 (the year ended Dec 31, 2025), against $164.1 million the year before (+60.6%). Source: the 10-K filed with the SEC on Feb 24, 2026. SEC
- What was IOVANCE BIOTHERAPEUTICS, INC. (IOVA)'s gross profit in fiscal 2025?
- IOVANCE BIOTHERAPEUTICS, INC. (IOVA) reported gross profit of $90.3 million for fiscal 2025 (the year ended Dec 31, 2025), against $70.8 million the year before (+27.5%). Source: the 10-K filed with the SEC on Feb 24, 2026. SEC
- What was IOVANCE BIOTHERAPEUTICS, INC. (IOVA)'s operating income in fiscal 2025?
- IOVANCE BIOTHERAPEUTICS, INC. (IOVA) reported operating income of -$403.4 million for fiscal 2025 (the year ended Dec 31, 2025), against -$395.3 million the year before. Source: the 10-K filed with the SEC on Feb 24, 2026. SEC
- What was IOVANCE BIOTHERAPEUTICS, INC. (IOVA)'s net income in fiscal 2025?
- IOVANCE BIOTHERAPEUTICS, INC. (IOVA) reported net income of -$391 million for fiscal 2025 (the year ended Dec 31, 2025), against -$372.2 million the year before. Source: the 10-K filed with the SEC on Feb 24, 2026. SEC
- What was IOVANCE BIOTHERAPEUTICS, INC. (IOVA)'s cash from operating activities in fiscal 2025?
- IOVANCE BIOTHERAPEUTICS, INC. (IOVA) reported cash from operating activities of -$302.4 million for fiscal 2025 (the year ended Dec 31, 2025), against -$353 million the year before. Source: the 10-K filed with the SEC on Feb 24, 2026. SEC
- What was IOVANCE BIOTHERAPEUTICS, INC. (IOVA)'s free cash flow in fiscal 2025?
- IOVANCE BIOTHERAPEUTICS, INC. (IOVA) reported free cash flow of -$336.2 million for fiscal 2025 (the year ended Dec 31, 2025), against -$364 million the year before. Source: the 10-K filed with the SEC on Feb 24, 2026. SEC
- What are IOVANCE BIOTHERAPEUTICS, INC. (IOVA)'s total assets?
- As of Dec 31, 2025, IOVANCE BIOTHERAPEUTICS, INC. (IOVA) reported total assets of $913.2 million, against $910.4 million a year earlier (+0.3%). Source: the 10-K filed with the SEC on Feb 24, 2026. SEC
- What are IOVANCE BIOTHERAPEUTICS, INC. (IOVA)'s total liabilities?
- As of Dec 31, 2025, IOVANCE BIOTHERAPEUTICS, INC. (IOVA) reported total liabilities of $214.6 million, against $200 million a year earlier (+7.3%). Source: the 10-K filed with the SEC on Feb 24, 2026. SEC
- What are IOVANCE BIOTHERAPEUTICS, INC. (IOVA)'s cash and cash equivalents?
- As of Dec 31, 2025, IOVANCE BIOTHERAPEUTICS, INC. (IOVA) reported cash and cash equivalents of $163.1 million, against $115.7 million a year earlier (+41%). Source: the 10-K filed with the SEC on Feb 24, 2026. SEC
Read from the FinancialMD API on Nov 13, 2026. Values change only when a new filing is made; see the Financials tab for every period and as-of replay.
The same numbers for an agent, with proof on every value:
curl "https://api.financial.md/v1/company/financials/income_statement/standardized?company=ticker:IOVA&period_type=annual&limit=5"Information only, not investment advice.